Want to see GMED full AI Analyst Report?
GMED Stock Chart & Stats
$83.10
$1.07(1.42%)
At close: 4:00 PM EDT
$83.10
$1.07(1.42%)
Day’s Range― - ―
52-Week Range$54.15 - $101.40
Previous CloseN/A
Volume1.71M
Average Volume (3M)1.36M
Market Cap
$10.10B
Enterprise Value$10.37K
Total Cash (Recent Filing)$595.14M
Total Debt (Recent Filing)$111.19M
Price to Earnings (P/E)18.7
Beta0.74
Next Earnings
Nov 10, 2026EPS Estimate
1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.97
Shares Outstanding111,831,820
10 Day Avg. Volume1,364,441
30 Day Avg. Volume1,364,691
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$102.55Price Target Upside23.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)4.98
Revenue Forecast (FY)$3.20B
Bulls Say, Bears Say
Bulls Say
Broad Revenue GrowthBroad-based growth across the core spine business and international markets indicates durable procedure demand and continued share capture. Expansion in both U.S. and overseas regions supports a diversified revenue base and provides room for sustained growth over the next several quarters.
Margin And Earnings ExpansionThe sharp improvement in gross margin, EBITDA margin, and earnings shows meaningful operating leverage and synergy capture. If sustained, stronger profitability should increase internal funding for product development, commercial investment, and integration while improving earnings resilience.
Product And Technology MomentumStrong trauma growth, repeated product launches, and expanding robotic utilization demonstrate an active innovation pipeline and growing adoption of enabling technologies. These capabilities can deepen surgeon engagement, broaden the portfolio, and support recurring implant and procedure-related demand.
Bears Say
Margin VolatilityAlthough current profitability has recovered, the decline in gross margin versus 2025 and uneven historical results indicate that earnings power remains sensitive to product mix, pricing, or costs. Persistent volatility could limit confidence in the durability of future margin expansion.
Enabling Technology Revenue PressureThe shift from cash sales to flexible financing models changes the timing and visibility of reported revenue and near-term cash receipts. Even with deployment growth, delayed recognition could constrain top-line momentum until the installed base generates stronger implant pull-through.
Nevro Integration DragNevro’s declining sales and ongoing integration changes create a continuing drag on consolidated growth and execution. Recovery depends on trial volumes returning and operational adjustments taking hold, leaving uncertainty around how quickly the acquired business can contribute sustainably.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $54.15 and its highest was $101.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $10.10B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Nov 10, 2026 which is in 53 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Aug 06, 2026. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.099 by $0.241.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 1.2.
How many shares outstanding does Globus Medical have?
Globus Medical has 111,831,820 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $1.34 in its last earnings report, beating expectations of $1.099. Following the earnings report the stock price went up 1.566%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in GMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$102.55 (23.40% Upside)
$102.55 (23.40% Upside)
Blogger Sentiment
Bullish
GMED Sentiment 82%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 40.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
GMED Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.View all GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$102.55
▲(23.40% Upside)
Technical Analysis
Ownership Overview
0.74% Insiders
31.32% Mutual Funds
32.28% Other Institutional Investors
11.90% Public Companies and
Individual Investors